A950160 Share Price Performance
₩0
-40900.00 (-100.00%)
Price ₩0
Share Pricen/a
Kolon TissueGene, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
A950160 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Kolon TissueGene, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -2.27k
- 11.91%
- -3,733.25%
- 115.8%
About A950160
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockville, Maryland.